Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-05-19
2002-04-30
Clark, Deborah J. R. (Department: 1633)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S350000, C530S387100, C424S192100
Reexamination Certificate
active
06379927
ABSTRACT:
BACKGROUND OF THE INVENTION
Both the retinoblastoma gene (RB) and transcription factor E2F play a critical role in cell growth control (for a review, see Adams, P. & Kaelin, W.
Seminars in Cancer Biology
6:99-108 (1995)). The RB locus is frequently inactivated in a variety of human tumor cells. Reintroduction of a wild-type RB gene (e.g., Bookstein et al.
Science
247:712-715 (1990)) or RB protein (pRB) (e.g., Antelman et al.
Oncogene
10:697-704(1995)) into RBneg/RBmut cells can suppress growth in culture and tumorigenicity in vivo.
While E2F serves to activate transcription of S-phase genes, its activity is kept in check by RB. RB arrests cells by blocking exit from G into S-phase (for example, Dowdy et al.
Cell
73:499-511 (1993)) but the precise pathway of the arrest remains unclear.
Although E2F forms complexes with RB, complex formation is more efficient if an E2F-related protein, DP-1, is present. E2F-1 and DP-1 form stable heterodimers which bind to DNA (for example, Qin et al.
Genes and Dev
. 6-:953-964 (1992)). DP-1-E2F complexes serve to cooperatively activate transcription of E2F-dependent genes. Such transcription can be repressed by pRB in the same manner as E2F-1 or DP-1 activated transcription.
Transcriptional repression of genes by RB in some instances can be achieved by tethering pRB to a promoter. For example, GAL4-pRB fusions bind to GAL4 DNA binding domains and repress transcription from p53, Sp-1 or AP-1 elements (Adnane, et al.
J. Biol. Chem
. 270:8837-8843 (1995); Weintraub, et al.
Nature
358:259-261 (1995)). Sellers, et al. (
Proc. Natl. Acad. Sci
. 92:11544-11548 (1995)) disclosed fusions of amino acid residues 1-368 of E2F with amino acids 379-792 or 379-928 of RB.
Chang, et al. (
Science
267:518-521 (1995)) disclosed the use of a replication-defective adenovirus-RB construct in the reduction of neointima formation in two animal models of restenosis, a hyperproliferative disorders.
SUMMARY OF THE INVENTION
The instant invention provides the surprising result that a-fusion of an E2F polypeptide with an RB polypeptide is more efficient in repressing transcription of the E2F promoter than RB alone, and that such fusions can cause cell cycle arrest in a variety of cell types. Such fusions can thus address the urgent need for therapy of hyperproliferative disorders, including cancer.
One aspect of the invention is a polypeptide comprising a fusion of a transcription factor, the transcription factor comprising a DNA binding domain, and a retinoblastoma (RB) polypeptide, the RB polypeptide comprising a growth suppression domain. Another aspect of the invention is DNA encoding such a fusion polypeptide. The DNA can be inserted in an adenovirus vector.
In some embodiments of the invention, the transcription factor is E2F. The cyclin A binding domain of the E2F can be deleted or nonfunctional. The E2F can comprise amino acid residues about 95 to about 194 or about 95 to about 286 in some embodiments.
The retinoblastoma polypeptide can be wild-type RB, RB56, or a variant or fragment thereof. In some embodiments, the retinoblastoma polypeptide comprises amino acid residues of about 379 to about 928. Preferred amino acid substitutions of the RB polypeptide include residues 2, 608, 788, 807, and 811.
Another aspect of the invention is an expression vector comprising DNA encoding a polypeptide, the polypeptide comprising a fusion of a transcription factor, the transcription factor comprising a DNA binding domain, and a retinoblastoma (RB) polypeptide, the RB polypeptide comprising a growth suppression domain. In some embodiments a tissue-specific promoter is operatively linked to DNA encoding the fusion polypeptide. The tissue-specific promoter can be a smooth muscle alpha actin promoter.
Another aspect of the invention is a method for treatment of hyperproliferative disorders comprising administering to a patient a therapeutically effective dose of an E2F-RB fusion polypeptide. The hyperproliferative disorder can be cancer. In some embodiments the hyperproliferative disorder is restenosis. The fusion polypeptide and nucleic acid encoding the fusion polypeptide can be used to coat devices used for angioplasty.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/19768 (1993-10-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/06922 (1994-03-01), None
patent: WO 94/06923 (1994-03-01), None
patent: WO 9507708 (1995-03-01), None
Fueyo, et al., “Expression of exogenous p16/CDKN2 products growth arrest in a glioma cell line that does not express RB protein,” Proceedings of the American Association for Cancer Research, 37:A49 (1996).
Xu, et al., “Enhanced Tumor Suppressor Gene Therapy via eplication-deficient Adenivirus Vectors Expressing an N-Terminal Truncated Retinoblastoma Protein,”Cancer Research,56:2245-2249 (1996).
Krek et al., Cell, vol. 83, p. 1149-1158, Dec. 1995.*
Sellers et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp. 11544-11548, Dec. 1995.*
Adnane et al., The Journal of Biological Chemistry, vol. 270(15), pp. 8827-8843, Apr. 1995.*
Adams, P.D. et al., “Transcriptional control by E2F,”Cancer Biology6:99-108 (1995).
Adnane, J. et al., “The Retinoblastoma Susceptibility Gene Product Represses Transcription When Directly Bound to the Promoter,”J. Biol. Chem.270(15):8837-8843 (1995).
Antelman, D. et al., “Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein,”Oncogene10:697-704 (1995).
Arteaga, C.L. et al., “Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice,”Cancer Research56:1098-1103 (1996).
Babajko, S. et al., “Interplay of the Liver-Enriched Transacting Factors, DBP and HNF1, in the Transactivation of Human IGFBP-1 Promoter,”Biochem.&Biophys. Research Commun.196(1):480-486 (1993).
Banas, B. et al., “Analysis of the promoter of the human prostatic acid phosphatase gene,”Biochim. Biophy. Acta1217:188-194 (1994).
Beijersbergen, R.L. et al., “E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo,”Genes&Devel.8:2680-2690 (1994).
Bingle, C.D. et al., “Interaction of CCAAT/enhancer-binding protein &agr; and &bgr; with the rat caeruloplasmin gene promoter,”Biochem. J.294:473-479 (1993).
Bookstein, R. et al., “Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB Gene,”Science247:712-715 (1990).
Buck, V. et al., “Molecular and functional characterisation of E2F-5, a new member of the E2F family,”Oncogene11:31-38 (1995).
Chang, M.W. et al., “Cytostatic Gene Therapy for Vascular Proliferative Disorders with a Constitutively Active Form of the Retinoblastoma Gene Product,”Science267:518-522 (1995).
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury,”Lab. Invest.49(3) 327-333 (1983).
Cox, G.A. et al., “Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity,”Nature364:725-729 (1993).
Curiel, D.T. et al., “Adenovirus enhancement of transferrin-polylysine-mediated gene delivery,”Proc. Natl. Acad. Sci. U.S.A.88:8850-8854 (1991).
Dalesandro, J. et al., “Gene Therapy for Donor Hearts: Ex vivo Liposome-Mediated Transfection,”J. Thoracic and Cardiovascular Surgery111(2):416-422 (1996).
Dobrowolski, S.F. et al., “An E2F dominant negative mutant blocks E1A induced cell cycle progression,”Oncogene9:2605-2612 (1994).
Dowdy, S.F. et al., “Physical Interaction of the Retinoblastoma Protein with Human D Cyclins,”Cell73:499-511 (1993).
Dusetti, N.J. et al., “Structural Organization of the Gene Encoding the Rat Pancreatitis-associated Protein,”J. Biol. Chem.268(19):14470-14475 (1993).
Eisenberger, C.L. et al., “Differential Regulation of the Rat Phosphoenolpyruvate Carboxykinase Gene Expression in Several Tissues of Transgene Mice,”Mol. Cell Biol.12(3):1396-1
Antelman Douglas
Gregory Richard J.
Wills Kenneth N.
Canji Inc.
Chen Shin-Lin
Clark Deborah J. R.
Townsend and Townsend / and Crew LLP
LandOfFree
Retinoblastoma fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retinoblastoma fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retinoblastoma fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2931640